Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• * Locally advanced disease or at high risk for relapse
• No clinically or radiologically suspected metastases
• Prior lymphadenectomy required
• Meets at least 1 of the following criteria for poor prognosis:
• * Gleason score greater than 7
• * T3 or T4 disease
• * Prostate-specific antigen greater than 20 ng/mL
• * N1 disease
• PATIENT CHARACTERISTICS:
• Age
• Under 80
• Performance status
• ECOG 0-2
• Life expectancy
• More than 10 years
• Hematopoietic
• Absolute neutrophil count greater than 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• AST and ALT no greater than 1.5 times upper limit of normal (ULN)
• Bilirubin no greater than ULN
• Renal
• Creatinine less than 1.6 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Cardiovascular
• No uncontrolled or severe cardiovascular disease
• No prior thrombosis
• Pulmonary
• No prior pulmonary embolus
• Other
• No active infection
• No intolerance to aspirin
• No other prior malignancy except basal cell skin cancer
• No physical or psychological condition that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy
• Chemotherapy
• No prior chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy
• No prior hormonal therapy
• No other concurrent hormonal therapy
• Radiotherapy
• Not specified
• Surgery
• See Disease Characteristics
• Other
• No other concurrent anticancer therapy